Goodbody Health Inc.
(“Goodbody” or “Goodbody Health” the “Company” or the “Group”)
23rd August 2022
Goodbody Health Provides
Shareholders Update on Completion of Continuation
Goodbody Health (AQSE: GDBY) is pleased to confirm the completion of the Company’s continuation to Guernsey,
effective August 19th, 2022, as previously announced which changes the name from Goodbody Health Inc. to Goodbody Health Limited. Also as previously announced, the Company’s voluntary delisting from the CSE occurred at the close of trading on August 17, 2022 after the suspension of trading on the AQSE on August 16, 2022. Shortly
thereafter the ten for one share consolidation of the Company’s issued and outstanding shares became effective on August 18, 2022. Following the consolidation, and upon the re-commencement of trading on the AQSE, the Company will have 36,496,276 Ordinary Shares issued and outstanding.
Trading is anticipated to resume on the AQSE on Wednesday, the 24th August 2022 following the continuation.
The Company has published Frequently Asked Questions (FAQs) in regards to the information and the continuation procedures relevant to shareholders on its website to be found at https://goodbodyhealth.com/agm-proposed-re-domiciliation/
Geremy Thomas, Executive Chairman, said: “This move is part of a simplification of the business, allowing the
company management to focus on the London market and the growth of the diagnostic testing business. We look forward to exciting times ahead.”.
The Directors of the Company accept responsibility for the contents of this announcement.
On behalf of the Board of Directors,
For further information:
Chief Executive Officer
Goodbody Health Ltd.
+44 (0) 20 7971 1255
AQSE Corporate Advisor
Peterhouse Capital Limited
Guy Miller / Mark Anwyl
+44 (0) 20 7469 0930